1-(5-amino-2,4-difluorophenyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | 179739-41-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(5-amino-2,4-difluorophenyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
• 英文别名: 1-(3-amino-4,6-difluorophenyl)-7-chloro-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid；1-(5-amino-2,4-difluorophenyl)-7-chloro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
• CAS: 179739-41-4
• 化学式: C₁₅H₇ClF₃N₃O₃
• 分子量: 369.687
• InChiKey: LRLCUJUKUQSKGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96.5
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1-(5-amino-2,4-difluorophenyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 在 吡啶 、 甲胺 作用下， 以 乙醇 为溶剂， 生成 1-(5-amino-2,4-difluorophenyl)-6-fluoro-7-methylamino-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic Acid
  参考文献：
  名称：

  Pyridonecarboxylic acid derivatives or salts thereof and drugs

  摘要：

  该发明涉及由通式（1）表示的吡啶酮羧酸衍生物：##STR1##其中R.sup.1为--OH、羧保护基团或（烷基）氨基团，R.sup.2为H或--NO.sub.2、（保护）氨基、（保护）羟基、较低烷基或较低烷氧基团，R.sup.3为卤素原子、H或--NO.sub.2、较低烷基、较低烷氧基或氨基团，R.sup.4为偶氮基、（取代）叠氮基、（取代）氨基、较低烷氧基或羟基团，R.sup.5、R.sup.6和R.sup.7独立地为H、--NO.sub.2、卤素原子或较低烷基团，R.sup.8为--NO.sub.2、（取代）氨基、--OH或较低烷氧基团，A为N或C--R.sup.12，其中R.sup.12为H、卤素原子或（取代）较低烷基、较低烯基、较低炔基、较低烷氧基、较低硫代烷基或硝基团，B为N或C--R.sup.13，其中R.sup.13为H或卤素原子，或其盐，以及包括此类化合物作为活性成分的药物。这些衍生物或其盐表现出优异的抗菌作用和口服吸收性，几乎不会引起副作用，并且易于合成。

  公开号：

  US06136823A1
• 作为产物：
  描述：

  ethyl 1-(3-amino-4,6-difluorophenyl)-7-chloro-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate 在 盐酸 、 溶剂黄146 作用下， 以 水 为溶剂， 生成 1-(5-amino-2,4-difluorophenyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  Pyridonecarboxylic acid derivatives or salts thereof and antibacterial

  摘要：

  该发明提供了以下一般式（1）的吡啶酮羧酸衍生物： 其中R.sup.1是氢原子或羧基保护基，R.sup.2是硝基或取代或未取代的氨基，R.sup.3是卤素原子，R.sup.4和R.sup.5中的每一个，可以相同也可以不同，是氢原子、卤素原子、低烷基基团或低烷氧基团，A是氮原子或--CX.dbd.，其中X是氢原子、卤素原子、低烷基基团或低烷氧基团，Z是卤素原子或饱和环状氨基团，可能带有取代基，或其盐以及包含其的抗菌剂。

  公开号：

  US05910498A1

文献信息

• NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：WAKUNAGA SEIYAKU KABUSHIKI KAISHA

  公开号：EP0787720A1

  公开（公告）日：1997-08-06

  The invention provides a pyridonecarboxylic acid derivative of the following general formula (1): wherein R1 is a hydrogen atom or carboxy protecting group, R2 is a nitro or substituted or unsubstituted amino group, R3 is a halogen atom, each of R4 and R5, which may be the same or different, is a hydrogen atom, halogen atom, lower alkyl group or lower alkoxy group, A is a nitrogen atom or - CX= wherein X is a hydrogen atom, halogen atom, lower alkyl group or lower alkoxy group, and Z is a halogen atom or a saturated cyclic amino group which may have a substituent, or a salt thereof and an antibacterial agent comprising the same.

  本发明提供了以下通式(1)的吡啶甲酸衍生物： 其中 R1 是氢原子或羧基保护基团，R2 是硝基或取代或未取代的氨基，R3 是卤素原子，R4 和 R5（可以相同或不同）各自是氢原子、卤素原子、低级烷基或低级烷氧基，A 是氮原子或 - CX= 其中 X 是氢原子、卤素原子、低级烷基或低级烷氧基，Z 是卤素原子或饱和环状氨基（可以有取代基），或其盐以及由其组成的抗菌剂。
• NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：EP0945435A1

  公开（公告）日：1999-09-29

  The invention relates to pyridonecarboxylic acid derivatives represented by the general formula (1): wherein R1 is -OH, a carboxy-protecting group or (alkyl)-amino group, R2 is H, or -NO2, (protected) amino, (protected) hydroxyl, lower alkyl or lower alkoxyl group, R3 is a halogen atom, H, or -NO2, lower alkyl, lower alkoxyl or amino group, R4 is an azido, (substituted) hydrazino, (substituted) amino, lower alkoxyl or hydroxyl group, R5, R6 and R7 are independently H, -NO2, halogen atom or lower alkyl group, R8 is a -NO2, (substituted) amino, -OH or lower alkoxyl group, A is N or C-R12, in which R12 is H, halogen atom, or (substituted) lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, lower alkylthio or nitro group, and B is N or C-R13, in which R13 is H or halogen atom, or salts thereof, and medicine comprising such a compound as an active ingredient. The derivatives or the salts thereof exhibit excellent antibacterial action and peroral absorbability, scarcely cause side effects, and are easy of synthesis.

  本发明涉及通式（1）所代表的吡啶甲酸衍生物： 其中 R1 是-OH、羧基保护基团或（烷基）-氨基；R2 是 H、或-NO2、（保护）氨基、（保护）羟基、低级烷基或低级烷氧基；R3 是卤素原子、H、或-NO2、低级烷基、低级烷氧基或氨基；R4 是叠氮基、（取代的）肼基、（取代的）氨基、低级烷氧基或羟基；R5、R6 和 R7 独立地是 H、-NO2、A是N或C-R12，其中R12是H、卤素原子或（取代的）低级烷基、低级烯基、低级炔基、低级烷氧基、低级烷硫基或硝基，B是N或C-R13，其中R13是H或卤素原子，或其盐，以及包含此类化合物作为活性成分的药物。这些衍生物或其盐具有出色的抗菌作用和口腔吸收性，几乎不会产生副作用，而且易于合成。
• A Novel Antibacterial 8-Chloroquinolone with a Distorted Orientation of the N1-(5-Amino-2,4-difluorophenyl) Group
  作者：Yasuhiro Kuramoto、Yoshihiro Ohshita、Jiro Yoshida、Akira Yazaki、Motoo Shiro、Tohru Koike

  DOI：10.1021/jm0205090

  日期：2003.5.1

  Fluoroquinolones represent a major class of antibacterial agents with great therapeutic potential. In this study, we designed m-aminophenyl groups as novel N-1 substituents of naphthyridones and quinolones. Among newly synthesized compounds, 7-(3-aminoazetidin-1-yl)-1-(5-amino-2,4-difluorophenyl)-8-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4) has extremely potent antibacterial activities against Gram (+) as well as Gram (-) bacteria. This compound is significantly more potent than trovafloxacin against clinical isolates: 30 times against Streptococcus pneumoniae and 128 times against methicillin resistant Staphylococcus aureus. The structure-activity relationship (SAR) study revealed that a limited combination of 1-(5-amino-2,4-difluorophenyl) group, 7-(azetidin-1-yl) group, and 8-Cl atom (or Br atom or Me group) gave potent antibacterial activity. An X-ray crystallographic study of a 7-(3-ethylaminoazetidin-1-yl)-8-chloro derivative demonstrated that the N-1 aromatic group was remarkably distorted out of the core quinolone plane by steric repulsion between the C-8 C1 atom and the N-1 substituent. Furthermore, a molecular modeling study of 4 and its analogues demonstrated that a highly distorted orientation was induced by a steric hindrance of the C-8 substituent, such as Cl, Br, or a methyl group. Thus, their highly strained conformation should be a key factor for the potent antibacterial activity.
• PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：WAKUNAGA SEIYAKU KABUSHIKI KAISHA

  公开号：EP0787720B1

  公开（公告）日：2003-07-16
• US5910498A
  申请人：——

  公开号：US5910498A

  公开（公告）日：1999-06-08